Cuprous oxide nanoparticles inhibit the growth of cervical carcinoma by inducing autophagy
Metrics: HTML 1474 views | ?
Leilei Xia1,*, Ye Wang2,*, Ya Chen3, Jiuqiong Yan1, Fan Hao1, Xiaoling Su1, Caihong Zhang1 and Mingjuan Xu1
1Department of Obstetrics and Gynaecology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, P.R. China
2Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, P.R. China
3Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
*These authors have contributed equally to this work
Mingjuan Xu, email: firstname.lastname@example.org
Keywords: cuprous oxide nanoparticle, cervical cancer, nanomedicine, therapy, AKT/mTOR pathway
Abbreviations: DDP: Cisplatin.
Received: February 13, 2017 Accepted: April 12, 2017 Published: May 15, 2017
Cervical carcinoma is one of the main causes of women’s cancer, and substantial side effects from standard treatment including platinum-based chemotherapy limit the options for escalation. In this paper, using cervical cancer cell lines and tumor-bearing mice as models, we report that CONPs could inhibit the proliferation of cancer cells in vitro and in vivo. Especially CONPs could inhibit tumor growth as cisplatin without weight loss. CONPs could also induce autophagy through AKT/mTOR pathway, which demonstrates that CONPs has the potential clinical applications.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.